PD2M Emerging Modalities Technical Program
The program is subject to change. Last updated on 5/20/2021. All times in EST.
...
The program is subject to change. Last updated on 5/20/2021. All times in EST.
| 1:00 PM - 1:05 PM | Opening Remarks | |
| 1:05 PM - 2:15 PM | SESSION 1: Peptide Therapies | |
| 1:05 PM - 1:25 PM | Brad Pentelute, MIT | |
| 1:25 PM - 1:35 PM | Q&A with Brad Pentelute, MIT | |
| 1:35 PM - 1:55 PM |
Kevin Seibert, Eli Lilly Developing a Novel Platform for Synthetic Peptide Manufacture Using Continuous Synthesis Methodologies |
|
| 1:55 PM - 2:05 PM | Q&A with Kevin Seibert, Eli Lilly | |
| 2:05 PM - 2:15 PM | "Coffee" Break | |
| 2:15 PM - 3:25 PM | SESSION 2: RNA, Cell, and Gene Therapies | |
| 2:15 PM - 2:35 PM | Jennitte Stevens, Amgen | |
| 2:35 PM - 2:45 PM | Q&A with Jennitte Stevens, Amgen | |
| 2:45 PM - 3:05 PM |
Janine Tom, Amgen siRNA as an Emerging Modality |
|
| 3:05 PM - 3:15 PM | Q&A with Janine Tom, Amgen | |
| 3:15 PM - 3:30 PM | Wrap Up Comments |